CHF
MCID: CNG034
MIFTS: 69

Congestive Heart Failure (CHF)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Congestive Heart Failure

MalaCards integrated aliases for Congestive Heart Failure:

Name: Congestive Heart Failure 12 74 29 6 15 37 17 71 32
Heart Failure 44 71
Cardiac Failure Congestive 12
Congestive Heart Disease 12
Heart Failure Congestive 54
Weak Heart 12
Chf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6000
ICD9CM 34 428 428.0
MeSH 44 D006333
NCIt 50 C3080 C50577
SNOMED-CT 67 155374007 195108009
ICD10 32 I50 I50.0 I50.9
UMLS 71 C0018801 C0018802

Summaries for Congestive Heart Failure

Disease Ontology : 12 A heart disease that is characterized by any structural or functional cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body.

MalaCards based summary : Congestive Heart Failure, also known as heart failure, is related to orthostatic intolerance and pulmonary edema, and has symptoms including tremor, angina pectoris and chest pain. An important gene associated with Congestive Heart Failure is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Cardiac conduction. The drugs Vitamin K1 and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include Adipose and Lateral Plate Mesoderm, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Heart failure (HF), also known as congestive heart failure (CHF), decompensatio cordis (DC), and... more...

Related Diseases for Congestive Heart Failure

Diseases related to Congestive Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1447)
# Related Disease Score Top Affiliating Genes
1 orthostatic intolerance 32.5 REN EDN1 AGTR1 ADRB1 ADRA2C ACE
2 pulmonary edema 32.5 REN NPPB NPPA KNG1 EDN1 AGTR1
3 peripartum cardiomyopathy 32.4 TTN MYH7 ADRB1 ACE
4 barth syndrome 32.3 TTN MYH7 MYH6
5 cardiac arrest 32.3 TTN REN NPPB MYH7 KNG1 ACE
6 cardiomyopathy, familial hypertrophic, 1 32.2 TTN MYH7 MYH6 CACNA1C
7 twin-to-twin transfusion syndrome 32.2 REN NPPA AGTR1
8 mitral valve insufficiency 32.1 TTN REN NPPB NPPA MYH7 MYH6
9 atrial standstill 1 32.1 VCL TTN NPPB MYH7 MYH6 ADRB1
10 sleep apnea 32.1 REN NPPB EDN1 ACE
11 progressive familial heart block 32.0 MYH7 MYH6 CACNA1C
12 cardiac conduction defect 32.0 MYH7 MYH6 CACNA1C
13 hypertensive heart disease 32.0 REN NPPB NPPA AGTR1 ACE
14 central sleep apnea 32.0 REN NPPB NPPA ACE
15 left bundle branch hemiblock 32.0 REN NPPB ACE
16 myocarditis 31.9 TTN NPPB MYH6 ACE
17 heart valve disease 31.9 REN NPPB NPPA MYH6 ACE
18 tricuspid valve insufficiency 31.9 REN NPPB EDN1 ACE
19 arteries, anomalies of 31.9 REN EDN1 AGTR1 ACE
20 atrial fibrillation 31.8 TTN NPPB NPPA MYH7 AGTR1 ADRB1
21 cardiogenic shock 31.8 NPPB ADM
22 mitral valve disease 31.8 REN NPPB NPPA AGTR1 ACE
23 angina pectoris 31.8 NPPB KNG1 EDN1 ACE
24 systolic heart failure 31.8 TTN NPPB NPPA EDN1 ADRB1 ACE
25 aortic valve insufficiency 31.7 REN NPPB NPPA ACE
26 mitral valve stenosis 31.7 REN NPPB NPPA EDN1 ACE
27 pericardial effusion 31.6 REN NPPB NPPA ACE
28 dilated cardiomyopathy 31.6 VCL TTN REN NPPC NPPB NPPA
29 pulmonary hypertension 31.6 REN NPPC NPPB NPPA EDN1 AGTR1
30 acute kidney failure 31.6 REN NPPA KNG1
31 pure autonomic failure 31.6 REN NPPA ACE
32 diastolic heart failure 31.6 TTN REN NPPB NPPA AGTR1 ACE
33 end stage renal disease 31.5 REN NPPB AGTR1 ACE
34 kidney disease 31.5 REN NPPC NPPB NPPA EDN1 AGTR1
35 vascular disease 31.5 REN NPPB KNG1 EDN1 ACE
36 body mass index quantitative trait locus 11 31.5 REN KNG1 EDN1 ADRB1 ACE ABCC8
37 chronic kidney disease 31.5 REN NPPC NPPB NPPA EDN1 AGTR1
38 atrioventricular block 31.5 TTN NPPB MYH7 CACNA1C ACE
39 acute myocardial infarction 31.4 NPPB NPPA EDN1 CDKN2B-AS1 AGTR1 ADM
40 chagas disease 31.4 NPPB ADRB1 ACE
41 heart disease 31.4 TTN REN NPPC NPPB NPPA MYH7
42 patent ductus arteriosus 1 31.4 REN NPPB MYH6 EDN1 ACE
43 conn's syndrome 31.3 REN NPPA AGTR1 ACE
44 right bundle branch block 31.3 NPPB CACNA1C ACE
45 hypertrophic cardiomyopathy 31.3 VCL TTN REN NPPB NPPA MYH7
46 respiratory failure 31.3 TTN REN NPPB NPPA MYH7 EDN1
47 sexual disorder 31.3 REN EDN1 ACE
48 ischemia 31.3 NPPB KNG1 EDN1 ADM ACE
49 constrictive pericarditis 31.3 TTN REN NPPB ACE
50 atrial heart septal defect 31.2 NPPB NPPA MYH7 MYH6 EDN1 ACE

Graphical network of the top 20 diseases related to Congestive Heart Failure:



Diseases related to Congestive Heart Failure

Symptoms & Phenotypes for Congestive Heart Failure

UMLS symptoms related to Congestive Heart Failure:


tremor, angina pectoris, chest pain, syncope, edema, equilibration disorder

MGI Mouse Phenotypes related to Congestive Heart Failure:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
2 homeostasis/metabolism MP:0005376 10.03 ABCC8 ACE ADM ADRA2C ADRB1 AGTR1
3 mortality/aging MP:0010768 9.77 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
4 muscle MP:0005369 9.32 ADM ADRB1 CACNA1C EDN1 MYH6 MYH7

Drugs & Therapeutics for Congestive Heart Failure

Drugs for Congestive Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 622)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin K1 Approved, Investigational Phase 4 84-80-0 5284607
2
Budesonide Approved Phase 4 51333-22-3 63006 5281004
3
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
4
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
5 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
9
Chlorthalidone Approved Phase 4 77-36-1 2732
10
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
11
Zolpidem Approved Phase 4 82626-48-0 5732
12
Promethazine Approved, Investigational Phase 4 60-87-7 4927
13
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
14
Testosterone enanthate Approved Phase 4 315-37-7 9416
15
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
16
Testosterone Approved, Investigational Phase 4 58-22-0 6013
17
Methyltestosterone Approved Phase 4 58-18-4 6010
18
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
19
Ramipril Approved Phase 4 87333-19-5 5362129
20
Captopril Approved Phase 4 62571-86-2 44093
21
Alogliptin Approved Phase 4 850649-61-5 11450633
22
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
23
Saxagliptin Approved Phase 4 361442-04-8 11243969
24
Linagliptin Approved Phase 4 668270-12-0 10096344
25
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
26
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
27
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
28
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
29
Trandolapril Approved Phase 4 87679-37-6 5484727
30
Ledipasvir Approved Phase 4 1256388-51-8 67505836
31
Terbutaline Approved Phase 4 23031-25-6 5403
32
Clonidine Approved Phase 4 4205-90-7 2803
33
Lactitol Approved, Investigational Phase 4 585-86-4 157355
34
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
36
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
37
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
38
Bumetanide Approved Phase 4 28395-03-1 2471
39
Racepinephrine Approved Phase 4 329-65-7 838
40
Norepinephrine Approved Phase 4 51-41-2 439260
41
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
42
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
43
Evolocumab Approved Phase 4 1256937-27-5
44
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
45
Indapamide Approved Phase 4 26807-65-8 3702
46
Amlodipine Approved Phase 4 88150-42-9 2162
47
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
48
tannic acid Approved Phase 4 1401-55-4
49
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
50
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986

Interventional clinical trials:

(show top 50) (show all 4130)
# Name Status NCT ID Phase Drugs
1 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
2 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
3 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
4 The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial Unknown status NCT01942109 Phase 4 Furosemide;Torasemide
5 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
6 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
7 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study Unknown status NCT00552851 Phase 4 pegvisomant
8 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
9 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Unknown status NCT03096613 Phase 4 Levothyroxine
10 Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure Unknown status NCT00988806 Phase 4 Levosimendan;Placebo
11 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
12 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
13 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
14 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
15 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
16 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
17 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
18 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
19 Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins Unknown status NCT02797340 Phase 4 Metformin
20 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
21 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
22 A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus Unknown status NCT03753087 Phase 4 Empagliflozin
23 A Pilot Feasibility Study in Recovered Heart Failure Unknown status NCT02859311 Phase 4 Withdrawal of therapy
24 Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure. DIVINE STUDY Unknown status NCT03709160 Phase 4 Bumetanide 1 MG
25 Resynchronization in Paced Heart Failure Patients With ICD Indication Unknown status NCT01415024 Phase 4
26 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
27 The Effect of Different Surgical Methods in the Treatment of Patients With Ischemic Mitral Regurgitation and Assess the Dynamics of Heart Failure and the Effectiveness of Surgical Treatment of Mitral Valve. Unknown status NCT01368575 Phase 4
28 Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic Unknown status NCT01930734 Phase 4 Dobutamine;Normal Saline
29 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
30 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
31 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
32 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
33 Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
34 Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Unknown status NCT03574857 Phase 4 Metolazone Oral Tablet;Chlorothiazide Injection
35 Remission From Stage D Heart Failure (RESTAGE-HF) Unknown status NCT01774656 Phase 4 Pharmacological Treatment
36 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
37 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
38 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor Unknown status NCT01156207 Phase 4 Aliskiren
39 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
40 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
41 Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure Unknown status NCT00527059 Phase 4 Levosimendan in addition to standard therapy;spironolactone, beta-blockers,ecc
42 Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study Unknown status NCT03209180 Phase 4 CarVeDilol-SR (Slow Release);Carvedilol IR (Immediate Release)
43 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
44 Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
45 The Effect of Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients Unknown status NCT03271879 Phase 4 Empagliflozin at a dose of 10 mg/day
46 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
47 Regional Tolvaptan Registry Unknown status NCT02666651 Phase 4 Tolvaptan
48 Latin America Cardiac Resynchronization Therapy Study Unknown status NCT01238874 Phase 4
49 Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy Unknown status NCT02166060 Phase 4 Ivabradine
50 A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events Unknown status NCT02762851 Phase 4 inactivated trivalent influenza vaccine

Search NIH Clinical Center for Congestive Heart Failure

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Atenolol
benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Captopril
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
coenzyme Q10
cyclothiazide
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam
Fenoldopam Mesylate
Fosinopril
Fosinopril Sodium
Furosemide
Growth Hormone
Hydralazine
Hydralazine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Inamrinone
inamrinone lactate
Indapamide
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol
Labetalol hydrochloride
Lisinopril
Losartan
Losartan Potassium
Methyclothiazide
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Milrinone
Milrinone Lactate
moexipril
Moexipril hydrochloride
Nadolol
Nitroglycerin
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
Polythiazide
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Sodium Nitroprusside
somatrem
Somatropin
SOMATROPIN (RECOMBINANT DNA ORIGIN)
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Trichlormethiazide
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Congestive Heart Failure cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Congestive Heart Failure:
ACP-01, autologous angiogenic precursor cells for cardiac diseases
Adipose-derived stem cells for treatment of congestive heart failure
BMAC, autologous bone marrow aspirate concentrate for congestive heart failure
Bone marrow-derived adult mononuclear cells for heart diseases
Cardiac progenitor cells for single-ventricle anomalies
Cardiosphere-derived autologous stem cells for reverse ventricular dysfunction
C-Cure, mesenchymal stem cell-derived cardiomyocytes for heart failure
CD133+ bone marrow-derived stem cells in conjuction with coronary artery bypass grafting
CD34+ stem cells for treatment of congestive heart failure
Enriched bone marrow-derived progenitor cells for heart diseases
ERCs, endometrial regenerative cells for congestive heart failure
Human cardiac-derived stem cell for the treatment of congestive heart failure
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesenchymal precursor cells for cardiovascular diseases
MyoCell, muscle stem cells for severe heart damage
Peripheral or bone marrow-derived stem cells for chronic heart failure
Embryonic/Adult Cultured Cells Related to Congestive Heart Failure:
Angiogenic cell precursors
Adipose-derived mesenchymal stem cells (family)
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 18351022 23788089 15995108
Bone marrow-derived mononuclear cells PMIDs: 20524773 20445812 19699857 22137069
Cardiac stem cells PMIDs: 17502484 14530411 18754813
Cardiac progenitor cells PMIDs: 17502484 14530411 18754813
Cardiosphere-derived cells PMIDs: 22336189
Cardiomyocyte-like cells PMIDs: 18835562 23583247
Bone marrow-derived CD133+ cells PMIDs: 17320570
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 16990384 18794392 22936827 23362308
Endometrial regenerative cells PMIDs: 18005405 23510656 20398245 19232091
Human cardiac stem cells PMIDs: 17502484 19038683 17150190
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 20850099 21155976
Skeletal myoblasts (MyoCell) PMIDs: 19051139 15615560 16446778
Bone marrow-derived mononuclear cells PMIDs: 20668107 21596713 19761394 22834565

Cochrane evidence based reviews: heart failure

Genetic Tests for Congestive Heart Failure

Genetic tests related to Congestive Heart Failure:

# Genetic test Affiliating Genes
1 Congestive Heart Failure 29

Anatomical Context for Congestive Heart Failure

MalaCards organs/tissues related to Congestive Heart Failure:

40
Heart, Bone Marrow, Endothelial, Skeletal Muscle, Bone, Thyroid, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Congestive Heart Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
2 Lateral Plate Mesoderm Splanchnic Mesoderm Pericytes Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Congestive Heart Failure

Articles related to Congestive Heart Failure:

(show top 50) (show all 58480)
# Title Authors PMID Year
1
Oxidative stress regulates left ventricular PDE5 expression in the failing heart. 54 61
20308615 2010
2
Effects of eythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. 61 54
18760492 2010
3
Provider adherence to clinical guidelines related to lipid-lowering medications. 61 54
20180482 2010
4
Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol. 61 54
20128603 2010
5
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction. 54 61
20391898 2010
6
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. 61 54
19763821 2010
7
Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. 61 54
19666591 2009
8
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 54 61
19560695 2009
9
Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. 61 54
19455052 2009
10
The clinical pharmacology of eplerenone. 54 61
19379127 2009
11
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. 54 61
19327624 2009
12
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. 61 54
19269262 2009
13
[The cardiorenal syndrome and optimal treatment of renal anemia]. 61 54
19370853 2009
14
Cardiac natriuretic peptides gene expression and secretion in inflammation. 61 54
19158604 2009
15
Brain natriuretic peptide (BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic ischemic heart failure. 61 54
19293536 2009
16
Porous silicon affinity chips for biomarker detection by MALDI-TOF-MS. 54 61
18948066 2008
17
Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. 54 61
17662495 2008
18
Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. 54 61
18620103 2008
19
Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern. 61 54
18514935 2008
20
Effect of erythropoietin in a patient with severe congestive heart failure--a case report. 54 61
18756924 2008
21
[Serum levels of fatty acid-binding protein and brain natriuretic peptide in children with pneumonia complicated by acute congestive heart failure]. 54 61
18554454 2008
22
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. 54 61
18458262 2008
23
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. 61 54
18353616 2008
24
Accuracy of the isovolumic relaxation time in the emergency diagnosis of new-onset congestive heart failure with preserved left ventricular systolic function in the setting of B-type natriuretic peptide levels in the mid-range. 54 61
17395301 2008
25
Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. 61 54
18446719 2008
26
A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. 54 61
18021271 2008
27
B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. 54 61
18347270 2008
28
Endomyocardial upregulation of beta1 adrenoreceptor gene expression and myocardial contractile reserve following cardiac resynchronization therapy. 54 61
18325466 2008
29
Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure. 54 61
19804290 2008
30
Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. 54 61
18219303 2008
31
Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment. 54 61
18215719 2008
32
[The role of urotensin II in human pathophysiology]. 61 54
19323069 2008
33
The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. 61 54
19128227 2008
34
Clinical correlates of very high brain natriuretic peptide levels in hospitalized patients. 54 61
18256556 2008
35
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. 61 54
18953278 2008
36
Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure. 54 61
17967592 2007
37
Low plasma levels of brain natriuretic peptide in severe acute heart failure: merely a case? 54 61
17382416 2007
38
The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. 54 61
17923351 2007
39
Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. 54 61
17892986 2007
40
Aldosterone and end-organ damage. 54 61
17683282 2007
41
Intermittent outpatient nesiritide infusion reduces hospital admissions in patients with advanced heart failure. 54 61
17875951 2007
42
ANP is cleared much faster than BNP in patients with congestive heart failure. 54 61
17479256 2007
43
Cardiotrophin-1 induces interleukin-6 synthesis in human monocytes. 54 61
17637508 2007
44
Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. 61 54
17361123 2007
45
Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean patients visiting emergency departments. 54 61
17452702 2007
46
Does quality of care for cardiovascular disease and diabetes differ by gender for enrollees in managed care plans? 54 61
17434752 2007
47
AMPD1 gene polymorphism and survival in patients with stable congestive heart failure. 61 54
17452134 2007
48
The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure. A study on 686 consecutive patients. 61 54
17452135 2007
49
Usefulness of bedside tissue Doppler echocardiography and B-type natriuretic peptide (BNP) in differentiating congestive heart failure from noncardiac cause of acute dyspnea in elderly patients with a normal left ventricular ejection fraction and permanent, nonvalvular atrial fibrillation: insights from a prospective, monocenter study. 61 54
17456069 2007
50
Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. 61 54
17223209 2007